Chia‐Chen Teng

Real-World Effect of Ruxolitinib Cream: Decreased Use of Additional Topical Therapies and Limited Escalation to Systemic Treatments

Abstract Introduction Ruxolitinib cream has demonstrated efficacy and safety in patients aged ≥ 2 years with mild to moderate atopic dermatitis (AD) in clinical trials. Early real-world data have demonstrated results consistent with clinical trial observations and have indicated...